首页> 外文期刊>Expert opinion on therapeutic targets >MMPs: a novel drug target for schizophrenia
【24h】

MMPs: a novel drug target for schizophrenia

机译:MMPs:精神分裂症的新型药物靶点

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Schizophrenia, a multifactorial disorder, is associated with dopaminergic hyperactivity, dysregulated glutamatergic neurotransmission, neuroinflammation and extracellular matrix (ECM) disturbances. MMPs, a group of structurally related proteolytic enzymes, are responsible for remodeling of ECM that maintains synaptic functions and blood-brain barrier (BBB) patency. Overstimulation of MMPs by neuroinflammation triggers ECM abnormalities that directly or indirectly alter neuronal functions like synaptic plasticity and damage to BBB. MMP-mediated ECM abnormality plays a central role in the pathogenesis of schizophrenia.
机译:简介:精神分裂症是一种多因素疾病,与多巴胺能亢进,谷氨酸能神经传递失调,神经炎症和细胞外基质(ECM)障碍有关。 MMP是一组与结构相关的蛋白水解酶,负责ECM的重塑,维持突触功能和血脑屏障(BBB)通畅。神经炎症对MMPs的过度刺激会触发ECM异常,从而直接或间接改变神经元功能,如突触可塑性和对BBB的损害。 MMP介导的ECM异常在精神分裂症的发病机理中起着核心作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号